Effects of finasteride on health-related quality of life in men with symptomatic benign prostatic hyperplasia

Girman, Cynthia J.; Kolman, Christopher; Liss, Charles L.; Bolognese, James A.; Binkowitz, Bruce; Stoner, Elizabeth

doi:10.1002/(sici)1097-0045(199608)29:2<83::aid-pros3>3.0.co;2-i

Cited by 35 publications

(10 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These data were in contradiction to those observed in a long-term ®nasteride study with regard to stimulation sexual function. 41 It is important to distinguish clinical sexual score assessment 42 from the patient's perception of his sexual life. In BPH a majority of patients do not complain about sexual function, but are still interested in treatments that are supposed to interfere least with their sexual life status.…”

Section: Discussionmentioning

confidence: 99%

Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice

Lukacs

Grange

Comet

et al. 1998

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

Objectives: To investigate (a) the magnitude and durability of symptom score reduction and HRQL score improvement (including sexual drive); (b) adverse outcomes; and (c) progression to acute urinary retention and prostate surgery up to three years of treatment with alfuzosin.Methods: Three thousand two hundred and twenty-eight BPH-patients out of 812 centers were included in a prospective three-year open-labelled study and treated with alfuzosin (immediate release formulation) at the recommended dosage. A symptom score (Boyarsky modi®ed) and a 20-item BPH speci®c HRQL score including three questions of sexuality (Urolife TM BPH QoL 20) were selfadministered at baseline, 3,6,12,18,24,30, and 36 months.Results: Two thousand ®ve hundred and seventy-nine patients (79.9%) completed the study at the end of three years. Symptom score was signi®cantly reduced by 54% at 3 months and this reduction was maintained up to 36 months (748.4%); HRQL score was signi®cantly improved by 45.4% at 12 months and this improvement was maintained up to 36 months ( 43.4%). Alfuzosin was well tolerated: the quantitative and qualitative distribution of adverse events was similar to that previously observed in placebo-controlled studies (vertigo/dizziness: 2.1%). Adverse events accounted for 4.2% of the drop-outs. 120 patients (3.7%) were operated on for BPH and nine patients (0.3%) experienced acute urinary retention.Conclusion: This medical outcomes study con®rms the long-term safety pro®le of alfuzosin in the naturalistic conditions of general practice and highlights the need to measure HRQL in the context of patient's preferences.

show abstract

Section: Discussionmentioning

confidence: 99%

Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice

Lukacs

Grange

Comet

et al. 1998

Prostate Cancer Prostatic Dis

View full text Add to dashboard Cite

show abstract

“…The relatively narrow four-point BII scale has been noted as a problem [108][109][110], as studies with enough patients to detect smaller differences are probably overpowered and risk detecting clinically insignificant differences in group mean scores.…”

Section: Functional Statusmentioning

confidence: 99%

“…The BII also excludes several aspects of the impact of BPH on function, giving the interpretation of the results a somewhat narrow scope. Therefore, a broader measure of everyday life in patients with BPH should be given more attention [110]. Even though the instrument has given clear positive indications of the effects of surgery on functional status, the seven-item BPH Interference with Activity [7] would possibly be even more useful, as it covers functional state in everyday life over a broader range.…”

Section: Functional Statusmentioning

confidence: 99%

Use and misuse of the concept of quality of life in evaluating surgical treatments for lower urinary tract symptoms

2003

View full text Add to dashboard Cite

OBJECTIVE To investigate how quality of life (QoL) components measured by given instruments direct the QoL perspective in treatment studies of lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH). METHODS Computer searches were conducted in Medline, CINAHL and Psychinfo; MeSH terms covering QoL and surgical treatments for BPH and LUTS were combined for the search. The analysis was based on a framework linking components of QoL to patient outcome. RESULTS Of the 74 papers meeting the inclusion criteria, 48 were published in 1997–2001, showing the increase of interest of the topic. Most of the papers reported the change in QoL by a one‐item scale, whilst only a few reported results from several of the components in the QoL concept. Some papers regarded the change in general health status or parts of health status as changes in QoL. Functional status and symptoms, and the bother of symptoms, were often regarded as indicators of a change in QoL. CONCLUSION These analyses show an increasing interest in measuring QoL after surgery for LUTS and BPH. In most of the studies analysed, the batteries of instruments selected were too narrow in scope to study the complexity of QoL. Most papers are based on instruments sensitive to change, but the reports do not distinguish the basic assumptions for understanding relationships important in QoL research and as a result, the reason for change is open to question.

show abstract

“…Participants included 2716 community-dwelling men age ≥ 71 years without any baseline self-reported functional limitation. LUTS severity (American Urologic Association Symptom Index) was classified as none/mild (score 0-7), moderate (8-19), and severe (20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35). At baseline and follow-up, men reported their ability to complete several mobility, activities of daily living (ADLs), and cognitiondependent tasks.…”

mentioning

confidence: 99%

Lower urinary tract symptoms and incident functional limitations among older community‐dwelling men

Bauer

Cawthon

Ensrud

et al. 2021

J American Geriatrics Society

View full text Add to dashboard Cite

Background: Lower urinary tract symptoms (LUTS) are associated with frailty phenotype, a risk factor for functional decline. Our objective was to determine the association between baseline LUTS and 2-year risk of new functional limitation among older men.Methods: We analyzed data from the Osteoporotic Fractures in Men (MrOS) study with baseline at Year 7 and follow-up through Year 9. Participants included 2716 community-dwelling men age ≥ 71 years without any baseline self-reported functional limitation. LUTS severity (American Urologic Association Symptom Index) was classified as none/mild (score 0-7), moderate (8-19), and severe (20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33)(34)(35). At baseline and follow-up, men reported their ability to complete several mobility, activities of daily living (ADLs), and cognitiondependent tasks. Risk was estimated for 3 incident functional limitation outcomes: (1) mobility (any difficulty walking 2-3 blocks or climbing 10 steps),

show abstract

Effects of finasteride on health-related quality of life in men with symptomatic benign prostatic hyperplasia

Cited by 35 publications

References 27 publications

Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice

Three-year prospective study of 3228 clinical BPH patients treated with alfuzosin in General Practice

Use and misuse of the concept of quality of life in evaluating surgical treatments for lower urinary tract symptoms

Lower urinary tract symptoms and incident functional limitations among older community‐dwelling men

Contact Info

Product

Resources

About